Paratek Pharmaceuticals rises after co reports surge in Q1 revenue
11/05/2020 12:20
** Shares of drug maker PRTK.O rise 2% to $4.75 premarket
after co reports a surge in Q1 revenue, smaller net loss
** PRTK reports Q1 revenue of $7.9 mln vs $1.5 mln a year
ago, driven by higher demand for its lead commercial drug Nuzyra
urn:newsml:reuters.com:*:nGNX3MRzRW
** Nuzyra, an antibiotic for treatment of community-acquired
bacterial pneumonia and acute bacterial skin infections,
generated net sales of $7.3 mln in the quarter
** In 2019, Paratek was awarded a contract from BARDA to
support development of Nuzyra for treatment of pulmonary anthrax
** Co reaffirms 2020 financial forecast
** Stock up ~15% YTD
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million